2011 (ots/PRNewswire)
[Missing Content]
Contact:
Media enquiries: Orla Barnewell, Tonic Life Communications, Tel:
+44 207 798 9915, orla.barnewell@toniclc.com; Helen Swift, Tonic Life
Communications, Tel: +44 207 798 9924, helen.swift@toniclc.com;
Patrick
Gorman, Ferring Pharmaceuticals, Tel: +41 (0) 58 301 00 53
patrick.gorman@ferring.com
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...
Amsterdam, The Netherlands (ots/PRNewswire) - - "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment" New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in ...
New gonadotrophin-releasing hormone (GnRH) receptor antagonist demonstrates rapid, long-term suppression of testosterone Saint-Prex (ots) - Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON® (degarelix), a new GnRH receptor antagonist ...